Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Neuroendocrine tumors (NETs) require a multidisciplinary approach in expert centers which optimize results improving care and survival.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Jimenez-Fonseca P, Vieitez J, Valdés N, Lauret M, Calvo-Temprano D,
Keywords: committee, indicator, multidisciplinary, resource,
Introduction: There are several effective drugs for advanced pancreatic neuroendocrine tumors (PNETs) but the right treatment sequence hasn’t been defined yet.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Solis-Hernandez M
Authors: Solis-Hernandez M, Calvo-Temprano D, Carmona-Bayonas A, García-Carbonero R, Custodio A,
Keywords: Sunitinib, targeted therapies,
Introduction: In PNET, phase III studies with antitarget drugs show few responses based on RECIST criteria despite a significant impact on progression free survival (PFS). Antiangiogenic drugs show in other tumors that responses are not always associated with a reduction in tumor volume on CT.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Solis-Hernandez M, Carmona-Bayonas A, Calvo-Temprano D, Nuñez B, Custodio A,
Introduction: Currently, there has been an improvement in diagnostic procedures and treatments of NET. Therefore, an effective teamwork is needed to choose the best approach for patients.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author:
Authors: Jimenez-Fonseca P, Avello N, Calvo-Temprano D, Fernández Llana B, García Bernardo C,
Keywords: Mutidisciplinary team, guideline, NET,
Introduction: Classically, the response assessment to systemic treatment is based on RECIST. In PNET treated with antiangiogenic targeted therapy as sunitinib there is no good correlation between response rate and progression free survival (PFS). Choi criteria might be an alternative to RECIST to evaluate the effect of sunitinib in patients with advanced PNET
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Solis Hernandez P
Authors: Solis Hernandez M, Calvo-Temprano D, Jiménez-Fonseca P, Faez L, Ruiz A,